Sign in →

Test ID: NGSFX Next-Generation Sequencing, Reflex from Acute Myeloid Leukemia 4- or 11-Gene Panels, Varies


Shipping Instructions


 



Necessary Information


 



Specimen Required


Only orderable as a reflex.  Reflex testing is available upon request within 6 months of original NGAMT / Next-Generation Sequencing Acute Myeloid Leukemia, Therapeutic Gene Mutation Panel (FLT3, IDH1, IDH2, TP53) or NGAML / Next-Generation Sequencing, Acute Myeloid Leukemia, 11-Gene Panel sample submission.

 

No additional specimen is required. This is a bioinformatics review of additional gene regions not analyzed in the previously ordered NGAMT / Next-Generation Sequencing Acute Myeloid Leukemia, Therapeutic Gene Mutation Panel (FLT3, IDH1, IDH2, TP53) or NGAML / Next-Generation Sequencing, Acute Myeloid Leukemia, 11-Gene Panel. Call 800-533-1710 for assistance with ordering.


Forms

Hematopathology Patient Information (T676) in Special Instructions

Useful For

When a more targeted gene panel test was initially performed in our laboratory, this test allows for comprehensive reanalysis of a larger set of genes/gene regions

 

Evaluation of hematologic neoplasms, specifically of myeloid origin (eg, acute myeloid leukemia, myelodysplastic syndrome, myeloproliferative neoplasm, myelodysplastic/myeloproliferative neoplasm) at the time of diagnosis or possibly disease relapse, to help determine diagnostic classification and provide prognostic or therapeutic information for clinical management

Testing Algorithm

Only orderable as a reflex. Reflex testing is available upon request within 6 months of original NGAMT / Next-Generation Sequencing Acute Myeloid Leukemia, Therapeutic Gene Mutation Panel (FLT3, IDH1, IDH2, TP53) or NGAML / Next-Generation Sequencing, Acute Myeloid Leukemia, 11-Gene Panel sample submission.

 

This is a bioinformatics and variant review only for the added gene regions.

 

See Targeted Genes Interrogated by OncoHeme Next-Generation Sequencing in Special Instructions for a list of the genes and exons targeted by this test. Call 800-533-1710 for assistance with ordering.

Method Name

Only orderable as a reflex. For more information see NGAMT / Next-Generation Sequencing Acute Myeloid Leukemia, Therapeutic Gene Mutation Panel (FLT3, IDH1, IDH2, TP53) or NGAML / Next-Generation Sequencing, Acute Myeloid Leukemia, 11-Gene Panel.

 

Somatic Mutation Detection by Next-Generation Sequencing (NGS)

Reporting Name

Reflex Analysis, NGSHM

Specimen Type

Varies

Specimen Stability Information

Specimen Type Temperature Time Special Container
Varies Varies 14 days

Clinical Information

Next-generation sequencing (NGS) is a comprehensive molecular diagnostic methodology that can interrogate multiple regions of genomic tumor DNA in a single assay. Many hematologic neoplasms are characterized by morphologic or phenotypic similarities, but can have characteristic somatic mutations in many genes. In addition, many myeloid neoplasms lack a clonal cytogenetic finding at diagnosis (normal karyotype) but can be diagnosed and classified according to the gene mutation profile. The presence and pattern of gene mutations can provide critical diagnostic, prognostic, and sometimes therapeutic information for the managing physicians.

Reference Values

Only orderable as a reflex. For more information see NGAMT / Next-Generation Sequencing Acute Myeloid Leukemia, Therapeutic Gene Mutation Panel (FLT3, IDH1, IDH2, TP53) or NGAML /  Next-Generation Sequencing, Acute Myeloid Leukemia, 11-Gene Panel.

 

An interpretive report will be provided.

Interpretation

Only orderable as a reflex within 6 months of initial testing. For more information see NGAMT / Next-Generation Sequencing Acute Myeloid Leukemia, Therapeutic Gene Mutation Panel (FLT3, IDH1, IDH2, TP53) or NGAML / Next-Generation Sequencing, Acute Myeloid Leukemia, 11-Gene Panel.

 

Mutations (gene alterations) identified, if present, using reference genome build GRCh37 (hg19). An interpretive report will be provided.

 

If this test is ordered in the setting of erythrocytosis and suspicion of polycythemia vera, interpretation requires correlation with a concurrent or recent prior bone marrow evaluation.

Clinical Reference

1. Patel JP, Levine RL: How do novel molecular genetic markers influence treatment decisions in acute myeloid leukemia? Hematology Am Soc Hematol Educ Program 2012;2012:28-34

2. Lindsley RC, Ebert BL: The biology and clinical impact of genetic lesions in myeloid malignancies. Blood 2013;23:3741-3748

3. Patel JP, Gonen M, Figueroa ME, et al: Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med 2012;366:1079-1089

4. Haferlach T, Nagata Y, Grossman V, et al: Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia 2014;28:241-247

5. Vainchenker W, Delhommeau F, Constantinescu SN, Bernard OA: New mutations and pathogenesis of myeloproliferative neoplasms. Blood 2011;118:1723-1735

Day(s) and Time(s) Performed

Monday, Wednesday, Friday

Analytic Time

14 days

Test Classification

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

CPT Code Information

81450

LOINC Code Information

Test ID Test Order Name Order LOINC Value
NGSFX Reflex Analysis, NGSHM In Process

 

Result ID Test Result Name Result LOINC Value
MP043 Specimen Type 31208-2
NFXID Diagnosis/Indication 29308-4
601695 NGSFX Result No LOINC Needed
601687 Pathogenic Mutations Detected 82939-0
601686 Interpretation 69047-9
601688 Clinical Trials 82786-5
601689 Variants of Unknown Significance 93367-1
601690 Additional Notes 48767-8
601691 Method Summary 49549-9
601692 Disclaimer 62364-5
601693 NGSFX Panel Gene List 36908-2
601694 Reviewed By: 18771-6
Mayo Clinic Laboratories | Hematology Catalog Additional Information:

mml-acute-leukemia